ArticleCureus2026
Acromegaly Secondary to Ectopic Growth Hormone-Releasing Hormone Secretion From Metastatic Bronchial Carcinoid Tumor: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchial carcinoid tumors are malignant neuroendocrine tumors that typically arise from enterochromaffin cells found in the epithelial lining of the lungs. We report a case of a 62-year-old female who was diagnosed with an atypical bronchial carcinoid tumor and subsequently underwent left pneumonectomy in December 2002. A year later, the patient developed metastases to the liver, bone, and pancreas. Over the subsequent decade, she developed clinical features of acromegaly and had persistently elevated insulin-like growth factor 1 (IGF-1) levels. Further investigation of the metastatic lesions revealed ectopic production of growth hormone-releasing hormone (GHRH). The patient underwent multiple cycles of chemotherapy for her metastatic lesions. She also continues to require long-term therapy with octreotide (Sandostatin) and pegvisomant to control IGF-1 levels. This case highlights the rarity of ectopic GHRH secretion from metastatic bronchial carcinoid tumors and emphasizes the importance of long-term surveillance and multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.